The Experts below are selected from a list of 79827 Experts worldwide ranked by ideXlab platform
Keith Wilner - One of the best experts on this subject based on the ideXlab platform.
-
metabolism and excretion of a new antipsychotic drug ziprasidone in humans
Drug Metabolism and Disposition, 1997Co-Authors: Chandra Prakash, Amin Kamel, Judith Gummerus, Keith WilnerAbstract:The pharmacokinetics, metabolism, and excretion of a new antipsychotic drug, ziprasidone, were studied in four normal male volunteers after oral administration of a single 20 mg dose of a mixture of 14C- and 3H-labeled ziprasidone. Blood, urine, and feces were collected at various intervals for determination of total Radioactivity and metabolic profiles. Eleven days after the dose, 20.3 ± 1% of the administered Radioactivity was recovered in the urine and 66.3 ± 4.8% in feces. The absorption of ziprasidone was rapid, and theCmax for ziprasidone and metabolites occurred at 2 to 6 hr postdose. Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0–t) of 335.7 ng · hr/ml. Mean peak serum concentration of total Radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0–t) of 724.6 ng-eq · hr/ml. On the basis of AUC(0–t) values, ∼46% of circulating Radioactivity was attributable to unchanged drug. Ziprasidone was extensively metabolized and only a small amount ( 90% of total Radioactivity recovered in urine.
-
metabolism and excretion of a new antipsychotic drug ziprasidone in humans
Drug Metabolism and Disposition, 1997Co-Authors: Chandra Prakash, Amin Kamel, Judith Gummerus, Keith WilnerAbstract:The pharmacokinetics, metabolism, and excretion of a new antipsychotic drug, ziprasidone, were studied in four normal male volunteers after oral administration of a single 20 mg dose of a mixture of 14C- and 3H-labeled ziprasidone. Blood, urine, and feces were collected at various intervals for determination of total Radioactivity and metabolic profiles. Eleven days after the dose, 20.3 +/- 1% of the administered Radioactivity was recovered in the urine and 66.3 +/- 4.8% in feces. The absorption of ziprasidone was rapid, and the C(max) for ziprasidone and metabolites occurred at 2 to 6 hr postdose. Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml. Mean peak serum concentration of total Radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml. On the basis of AUC(0-t) values, approximately 46% of circulating Radioactivity was attributable to unchanged drug. Ziprasidone was extensively metabolized and only a small amount ( 90% of total Radioactivity recovered in urine.
Chandra Prakash - One of the best experts on this subject based on the ideXlab platform.
-
metabolism and excretion of a new antipsychotic drug ziprasidone in humans
Drug Metabolism and Disposition, 1997Co-Authors: Chandra Prakash, Amin Kamel, Judith Gummerus, Keith WilnerAbstract:The pharmacokinetics, metabolism, and excretion of a new antipsychotic drug, ziprasidone, were studied in four normal male volunteers after oral administration of a single 20 mg dose of a mixture of 14C- and 3H-labeled ziprasidone. Blood, urine, and feces were collected at various intervals for determination of total Radioactivity and metabolic profiles. Eleven days after the dose, 20.3 ± 1% of the administered Radioactivity was recovered in the urine and 66.3 ± 4.8% in feces. The absorption of ziprasidone was rapid, and theCmax for ziprasidone and metabolites occurred at 2 to 6 hr postdose. Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0–t) of 335.7 ng · hr/ml. Mean peak serum concentration of total Radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0–t) of 724.6 ng-eq · hr/ml. On the basis of AUC(0–t) values, ∼46% of circulating Radioactivity was attributable to unchanged drug. Ziprasidone was extensively metabolized and only a small amount ( 90% of total Radioactivity recovered in urine.
-
metabolism and excretion of a new antipsychotic drug ziprasidone in humans
Drug Metabolism and Disposition, 1997Co-Authors: Chandra Prakash, Amin Kamel, Judith Gummerus, Keith WilnerAbstract:The pharmacokinetics, metabolism, and excretion of a new antipsychotic drug, ziprasidone, were studied in four normal male volunteers after oral administration of a single 20 mg dose of a mixture of 14C- and 3H-labeled ziprasidone. Blood, urine, and feces were collected at various intervals for determination of total Radioactivity and metabolic profiles. Eleven days after the dose, 20.3 +/- 1% of the administered Radioactivity was recovered in the urine and 66.3 +/- 4.8% in feces. The absorption of ziprasidone was rapid, and the C(max) for ziprasidone and metabolites occurred at 2 to 6 hr postdose. Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml. Mean peak serum concentration of total Radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml. On the basis of AUC(0-t) values, approximately 46% of circulating Radioactivity was attributable to unchanged drug. Ziprasidone was extensively metabolized and only a small amount ( 90% of total Radioactivity recovered in urine.
D Roulet - One of the best experts on this subject based on the ideXlab platform.
-
characterization of chemical composition and particle size distribution of aerosols released during laser cutting of fuel debris simulants
Journal of environmental chemical engineering, 2020Co-Authors: Claire Dazon, Emmanuel Porcheron, Christophe Journeau, C Suteau, Christophe Chagnot, I Doyen, E Excoffier, D RouletAbstract:Abstract We present here the results regarding the characterization of chemical composition and size distribution of aerosols released during laser cutting of two types of fuel debris simulants (Ex-Vessel and In-Vessel scenarios) in air and underwater conditions in the context of Fukushima Daiichi dismantling. The aerosols have systematically an aerodynamic mass median diameter below 1 μm, with particle sizes generally comprised between 60 nm and 160 nm for air cutting conditions, and larger diameters (300−400 nm) for underwater experiments. Regarding the chemical composition, iron, chromium and nickel are mainly found by more than 50 % in the samples whereas radioactive surrogates of Uranium (Hafnium) are undetectable. When compositions are transposed to Radioactivity, taking into account radioisotope inventories 10 years after the accident, it is well evidenced that the Radioactivity is carried out by small particles in air condition tests (median size around 100 nm) than underwater (median size around 400 nm): 50 % of the Radioactivity is present in particles below 90 nm, and 99 % below 950 nm. Caesium carries the largest part of the Radioactivity at all sizes below 1 μm in the case of an Ex-Vessel fuel debris simulant. For the In-Vessel, the aerosol median size for the Radioactivity is situated around 100 nm, with 59 % of the Radioactivity is carried by strontium, 17 % by barium and 16 % by minor actinides (modelled by cerium) and 7% by the caesium. For sizes above 1.6 μm, cerium representing alpha particles (surrogate of plutonium) is almost the only Radioactivity-bearing element (96–97 % of the Radioactivity). The data produced here could already be used for modelling or designing development of strategies to implement in-situ the laser cutting for fuel debris retrieval and safety associated strategies.
Seiji Hiraku - One of the best experts on this subject based on the ideXlab platform.
-
studies on the metabolic fate of ultra short acting β1 blocker ono 1101 2 plasma concentration time profile distribution excretion and effects on drug metabolizing enzyme activities after repeated intravenous administration to rats
Drug Metabolism and Pharmacokinetics, 1997Co-Authors: Ken Tsunekawa, Haruo Imawaka, Kiyoshi Natsui, Hiroaki Fujimoto, Masatsune Ishido, Kimio Shibakawa, Seiji HirakuAbstract:Plasma concentration-time profile, distribution and excretion of ONO-1101 after repeated intravenous administration were investigated in rats. Also the influence on the hepatic drug metabolizing enzyme activities was examined. 1. The Radioactivity in plasma at 24 hr after each intravenous administration of 14C-ONO-1101 at the dose of 1 mg/kg/day for 7 days was not detected or was around the detection limit. Repeated administration had no effect on plasma concentration-time profile. 2. Following repeated intravenous admini stration of 14C-ONO-1101 to male rats at the dose of 1 mg/kg, the kidney, liver, lung, trachea contained high levels of Radioactivity that declined to about or below detection limit in almost all tissues at 24 hr. Also in skin and carcass, a high degree of Radioactivity were observed within 15 min then declined. Compared with a single administration, the elimination of Radioactivity in kidney and liver was slightly delayed. But repeated intravenous administration was not associated with any accumulation of Radioactivity in organ or tissue. 3. The daily excretion of Radioactivity in urine and feces was constant since 4-th administration. After repeated intravenous administration, the excretion of Radioactivity into urine and feces was respectively 89.7, 14.9%, for male, 86.5, 17.0% for female rats. 4. Repeated intravenous administration of ONO-1101 at the doses of 1, 10, 50 mg/kg/day for 7 days had no effect on microsomal protein content, liver weight and hepatic drug metabolizing enzyme activities.
Judith Gummerus - One of the best experts on this subject based on the ideXlab platform.
-
metabolism and excretion of a new antipsychotic drug ziprasidone in humans
Drug Metabolism and Disposition, 1997Co-Authors: Chandra Prakash, Amin Kamel, Judith Gummerus, Keith WilnerAbstract:The pharmacokinetics, metabolism, and excretion of a new antipsychotic drug, ziprasidone, were studied in four normal male volunteers after oral administration of a single 20 mg dose of a mixture of 14C- and 3H-labeled ziprasidone. Blood, urine, and feces were collected at various intervals for determination of total Radioactivity and metabolic profiles. Eleven days after the dose, 20.3 ± 1% of the administered Radioactivity was recovered in the urine and 66.3 ± 4.8% in feces. The absorption of ziprasidone was rapid, and theCmax for ziprasidone and metabolites occurred at 2 to 6 hr postdose. Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0–t) of 335.7 ng · hr/ml. Mean peak serum concentration of total Radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0–t) of 724.6 ng-eq · hr/ml. On the basis of AUC(0–t) values, ∼46% of circulating Radioactivity was attributable to unchanged drug. Ziprasidone was extensively metabolized and only a small amount ( 90% of total Radioactivity recovered in urine.
-
metabolism and excretion of a new antipsychotic drug ziprasidone in humans
Drug Metabolism and Disposition, 1997Co-Authors: Chandra Prakash, Amin Kamel, Judith Gummerus, Keith WilnerAbstract:The pharmacokinetics, metabolism, and excretion of a new antipsychotic drug, ziprasidone, were studied in four normal male volunteers after oral administration of a single 20 mg dose of a mixture of 14C- and 3H-labeled ziprasidone. Blood, urine, and feces were collected at various intervals for determination of total Radioactivity and metabolic profiles. Eleven days after the dose, 20.3 +/- 1% of the administered Radioactivity was recovered in the urine and 66.3 +/- 4.8% in feces. The absorption of ziprasidone was rapid, and the C(max) for ziprasidone and metabolites occurred at 2 to 6 hr postdose. Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml. Mean peak serum concentration of total Radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml. On the basis of AUC(0-t) values, approximately 46% of circulating Radioactivity was attributable to unchanged drug. Ziprasidone was extensively metabolized and only a small amount ( 90% of total Radioactivity recovered in urine.